Skip to content
2000
Volume 20, Issue 10
  • ISSN: 1567-2050
  • E-ISSN: 1875-5828

Abstract

Psychosis and hyperactive behaviors, such as agitation and wandering, affect a significant proportion of patients with Alzheimer’s disease (AD). These symptoms are often treated with antipsychotics, usually in an off-label approach. This mini-review provides an updated perspective on the pharmacological approach for the neuropsychiatric symptoms (NPS) in AD. The results of new studies have provided a better understanding of AD-related NPS management, but high-quality evidence still needs to be obtained. Herein, we argue for a more cautious approach to the use of antipsychotics in AD and highlight the importance of exploring alternative treatments for NPS. By doing so, we can ensure that patients with AD receive optimal care that is both effective and safe.

Loading

Article metrics loading...

/content/journals/car/10.2174/0115672050287534240215052417
2023-10-01
2025-04-15
Loading full text...

Full text loading...

/content/journals/car/10.2174/0115672050287534240215052417
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test